Immune checkpoint inhibitor (CPI) therapy has transformed advanced and inoperable stage 3 non-small-cell lung cancer (NSCLC) outcomes. For operable early-stage NSCLC, despite a high relapse rate of 60% by 5 years,1 adjuvant chemotherapy only modestly improves the 5-year overall survival (OS) rate by 5.4%,1 and since its widespread implementation after 2002, little has changed to improve the cure rate for these patients.